Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

leted late last year. Data from this trial show encouraging durable anti-tumor activity in the 48 mg/m2 cohort, as measured by GOG RECIST criteria with partial and complete responses, and progression-free survival. Some of the patients dosed with 60 mg/m2 or 75 mg/m2 of voreloxin still remain on study and complete and partial responses have been observed. Voreloxin has generally been well tolerated at all three dose levels.
  • In March 2009, Sunesis sold to SARcode Corporation all of the company's interest in patents and know-how related to the LFA-1 inhibitors program previously licensed to SARcode for a total cash consideration of $2 million. Sunesis continues to hold a series of secured convertible notes issued by SARcode having a total principal value of $1 million.
  • In January 2009, Sunesis entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises for its prior company headquarters at 341 Oyster Point Boulevard in South San Francisco, CA. In consideration of the early termination of the existing lease agreement, Sunesis agreed to pay the lessor an aggregate fee of $2.2 million, thus substantially reducing its future financial liabilities, and the landlord retained the $0.3 million security deposit it received upon signing of the lease.
  • Sunesis filed today a Form 12b-25 with the Securities and Exchange Commission disclosing its inability to timely file its Annual Report on Form 10-K for the year ended December 31, 2008 due to the timing of the placement announced today. Sunesis intends to file its Annual Report on Form 10-K as soon as practicable, and in any event within the 15 day extension period afforded by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. As disclosed in the Form 12b-25, Sunesis expects to receive a "going concern" opinion from its independent registered public accounting firm when the Annual Report on Form 10-K is filed, whether or not the private p
    '/>"/>

  • SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
    (Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
    (Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
    (Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
    Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
    ... May 8, 2008, at,8:30 a.m. Eastern/2:30 p.m. Central ... (Nasdaq: CTIC ; MTA) management team will,host ... 2008 first,quarter achievements and financial results., ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific ...
    ... Ultrasound Applications for OB/GYN, NEW ORLEANS, ... highlights new products and solutions (booth,#1023) for ... and,Gynecologists Annual Meeting in New Orleans, May ... The latest member of the Siemens ...
    ... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... announced today that its Plexur(R) Technology will be,used ... Jeffrey Hollinger,of Carnegie Mellon University. This program, which ... Center for Biomaterials and Dr. Joachim Kohn of,Rutgers ...
    Cached Biology Technology:Siemens Showcases New ACUSON S2000 Ultrasound System, as Well as World's First Pocket Ultrasound System 2Siemens Showcases New ACUSON S2000 Ultrasound System, as Well as World's First Pocket Ultrasound System 3Osteotech's Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine 2Osteotech's Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine 3
    (Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia National ... testing safer, easier, faster and cheaper. , ... commonly found in soils all over the world and ... humans and animals. The bacteria can survive in harsh ... anthracis may occur through skin contact, inhalation of ...
    (Date:4/17/2014)... One day about eight years ago, Katia Silvera ... and her father were on a field trip in a ... orchid they had never seen before. , Unable to identify ... The orchid turned out to be an unnamed species. ... silverarum . , "Lophiaris" is the genus name, comprising about ...
    (Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
    Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
    ... What:,The Fourth AACR Conference on The Science of Cancer ... will bring together scientists to share the latest findings ... the needs of underserved populations. Cancer continues to strike ... working on ways to better understand the causes and ...
    ... MO, August 15, 2011A compound found in green tea ... treat two types of tumors and a deadly congenital ... led by Principal Investigator, Dr. Thomas Smith at The ... The Children,s Hospital of Philadelphia. Their findings are published ...
    ... that parasites in fish, including threatened species of Oregon coho ... has been assumed, and could be one of the key ... mortality. It,s not just the presence or absence of ... that can build up over years or decades and ultimately ...
    Cached Biology News:Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2Parasite loads an underlying cause of salmon mortality, linked to land use changes 2
    Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
    LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
    ...
    ... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
    Biology Products: